Contraception

Contraception · ISSN (e) 1879-0518 · 135 papers in corpus
observational 2010
doi:10.1016/j.contraception.2010.07.026 ·PMID:21397100

BACKGROUND: Experimental evidences suggest that metabolic activation and conversion of oral contraceptive pills (OCPs) to reactive species are responsible for their genotoxicity. The present study was undertaken to investigate the effects o…

review 2010
doi:10.1016/j.contraception.2009.12.012 ·PMID:20933118

Administration of mifepristone followed by the prostaglandin, misoprostol, has been used successfully in the medical termination of pregnancy for over 25 years, and the method is registered in 35 countries. Single doses of mifepristone are …

review 2010
doi:10.1016/j.contraception.2010.05.005 ·PMID:20933112

Non-contraceptive health benefits are now recognized as an important aspect of the overall impact of all hormonal contraceptives. The levonorgestrel-releasing intrauterine systems (LNG IUS) are particularly effective at producing a number o…

review 2010
doi:10.1016/j.contraception.2010.04.004 ·PMID:20933114

The synthetic progestins used for contraception so far are structurally related either to testosterone (estranes and gonanes) or to progesterone (pregnanes and 19-norpregnanes). Several new progestins have been designed to minimize side-eff…

rct 2009
doi:10.1016/j.contraception.2009.03.018 ·PMID:19835717

BACKGROUND: This study compared the bleeding pattern, cycle control and safety of an oral contraceptive (OC) comprising estradiol valerate/dienogest (E2V/DNG; administered using a dynamic dosing regimen) with a monophasic OC containing ethi…

rct 2009
doi:10.1016/j.contraception.2009.03.017 ·PMID:19835721

BACKGROUND: Obese women have higher rates of pregnancy complications, making the prevention of unintended pregnancies in this group of particular importance. STUDY DESIGN: We performed a secondary analysis of data from Active Mothers Postp…

rct 2009
doi:10.1016/j.contraception.2009.07.011 ·PMID:20004274

BACKGROUND: The effects of extended regimens of combined oral contraceptives (COC) on lipid parameters are largely unknown. The present study compared the effects of a COC containing 30 mcg ethinyl estradiol and 2 mg dienogest (EE/DNG) in c…

rct 2009
doi:10.1016/j.contraception.2009.08.003 ·PMID:20103448

BACKGROUND: The study was conducted to evaluate the cardiovascular risk markers associated with endometriosis and the influence of the levonorgestrel intrauterine system (LNG-IUS) compared with the GnRH analogue (GnRHa) leuprolide acetate o…

rct 2009
doi:10.1016/j.contraception.2008.07.017 ·PMID:19041438

BACKGROUND: Implanon has been reported to be effective in the treatment of dysmenorrhea. We compared the therapeutic efficacies of depot medroxyprogesterone acetate (DMPA) and Implanon with regard to pain relief in women with endometriosis.…

lab-animal 2009
doi:10.1016/j.contraception.2009.11.004 ·PMID:20227552

BACKGROUND: Ulipristal (UPA; CDB-2914) is a progesterone receptor modulator with contraceptive potential. To test its effects when delivered by an intrauterine system (IUS), we prepared control and UPA-filled IUS and evaluated their effects…

review 2009
doi:10.1016/j.contraception.2009.08.010 ·PMID:20004267

Previous attempts to replace ethinylestradiol (EE) with 17beta-estradiol (E2) in combined oral contraceptives (COCs) have proved unsatisfactory in terms of bleeding outcomes. A review of previous studies of E2-based COCs has shown that, des…

guideline 2009
doi:10.1016/j.contraception.2008.10.016 ·PMID:19185668

BACKGROUND: In the fall of 2007, the controversy about the contraceptive use of depot-medroxyprogesterone acetate (DMPA) and its potential impact on skeletal health reached the media in the province of Quebec, Canada, thereby becoming a mat…

lab-animal 2009
doi:10.1016/j.contraception.2009.01.003 ·PMID:19442786

BACKGROUND: The study was conducted to test the potential of using dienogest (DNG) plus testosterone undecanoate (TU) in rats for development of a once-a-month injectable male hormonal contraceptive. STUDY DESIGN: Dose selection studies we…

observational 2008
doi:10.1016/j.contraception.2008.07.002 ·PMID:19014794

BACKGROUND: The study was conducted to evaluate vascular endothelial growth factor (VEGF), Cox-2 and aromatase expression in the endometrium of uteri with myomas and other associated pathologies. STUDY DESIGN: Hysteroscopy was performed in…

rct 2008
doi:10.1016/j.contraception.2008.02.005 ·PMID:18477491

BACKGROUND: This study was conducted to investigate the effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on thyroid hormones and androgen parameters. STUDY DESIGN: Thyroid and androgen parameters were…

rct 2008
doi:10.1016/j.contraception.2008.06.015 ·PMID:18929735

BACKGROUND: The study was conducted to investigate the effect of a combined oral contraceptive (COC) containing 30 mcg ethinylestradiol and 2 mg dienogest with two different regimens on various hemostasis variables. STUDY DESIGN: Hemostati…

rct 2008
doi:10.1016/j.contraception.2008.10.010 ·PMID:19272497

BACKGROUND: Acne is a multifactorial disease characterized by androgenic stimulation of sebaceous glands. Therefore, combined oral contraceptives (COCs) containing anti-androgenic progestogens are suitable candidates for acne treatment. Thi…

lab-animal 2008
doi:10.1016/j.contraception.2008.05.003 ·PMID:18692618

BACKGROUND: Fundamental and genetic differences between women in the endometrium may cause some to develop endometriosis, whereas others do not. Oral contraceptives (OC) may have an effect on the endometrium, rendering the development of en…

nonrandomized-trial 2008
doi:10.1016/j.contraception.2008.11.004 ·PMID:19185671

BACKGROUND: The objective of this study was to evaluate the efficacy and side effects of the levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of moderate or severe dysmenorrhea associated with adenomyosis for a 3-year…

nonrandomized-trial 2007
doi:10.1016/j.contraception.2007.05.091 ·PMID:17707716

BACKGROUND: This study was conducted to evaluate the effect of the levonorgestrel-releasing intrauterine system (LNG-IUS) on adenomyotic lesions diagnosed and monitored by magnetic resonance imaging (MRI). STUDY DESIGN: LNG-IUS was inserte…

review 2007
doi:10.1016/j.contraception.2006.12.013 ·PMID:17531600

CONTEXT: Progestins delivered by a variety of routes have been demonstrated, in addition to their high contraceptive effect, to have substantial benefits in the treatment of various gynecological disorders, and the intrauterine route has pa…

review 2007
doi:10.1016/j.contraception.2006.12.008 ·PMID:17531605

OBJECTIVES: This report is a review of the medical literature on the use of the levonorgestrel-releasing intrauterine system (LNG-IUS) in women with endometriosis, adenomyosis, cyclic pelvic pain and dysmenorrhea. MATERIAL AND METHODS: A r…

rct 2006
doi:10.1016/j.contraception.2005.09.013 ·PMID:16730488

PURPOSE: This double-blind, placebo-controlled study was conducted to evaluate the efficacy of valdecoxib and placebo for controlling irregular uterine bleeding in depot-medroxyprogesterone acetate (DMPA) users. METHOD: A total of 51 DMPA …

review 2006
doi:10.1016/j.contraception.2006.01.016 ·PMID:16730484

It is known that women who smoke cigarettes and use oral contraceptives are more likely to have breakthrough bleeding than women who do not smoke. In this article, we review possible mechanisms by which cigarette smoke and its constituents …

2006
doi:10.1016/j.contraception.2006.05.016